SNDX News
Archived Headlines
- US IPO Weekly Recap: 2016 IPO market kicks off with a flurry of biotech filings 01/08/16
- Breast cancer biotech Syndax Pharmaceuticals refiles for an $86 million IPO 01/04/16
- Breast cancer biotech Syndax Pharmaceuticals withdraws $60 million IPO 01/22/15
- Cancer biotech Syndax Pharmaceuticals postpones IPO 06/27/14
Renaissance Capital's 1Q16 US IPO Market Review
The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing...read more
Syndax Pharmaceuticals prices IPO at $12, well below the range
Syndax Pharmaceuticals, which is developing a therapy that enhances checkpoint immuno-oncology drugs, raised $53 million by offering 4.4 million shares at $12, below the range of $14 to $16. Syndax Pharmaceuticals plans to list on the Nasdaq under the symbol...read more
Week ahead: IPO market still stuck in neutral
The IPO market remains in the doldrums this week, but the Renaissance IPO Index's 10% gain in the past two weeks suggests that the IPO train could start rolling again in March. Second time's a charm After a scrapped IPO attempt in June 2014,...read more
Second time's a charm: Syndax Pharmaceuticals sets terms for $66 million IPO
Syndax Pharmaceuticals, which is developing a therapy that enhances checkpoint immuno-oncology drugs, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $66 million by offering 4.4 million shares at a price range of $14 to...read more